A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)

Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple s...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Remington, Gina M., Treadaway, Katherine, Frohman, Teresa, Salter, Amber, Stüve, Olaf, Racke, Michael K., Hawker, Kathleen, Agosta, Federica, Sormani, Maria Pia, Filippi, Massimo, Frohman, Elliot M.
Format: Artigo
Langue:Inglês
Publié: SAGE Publications 2010
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002615/
https://ncbi.nlm.nih.gov/pubmed/21180632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609355851
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires